The interleukin-4 receptor (IL-4R) is emerging as a potential drug target, projected to potentially be worth up to 10 billion USD. In this article, ACROBiosystems discusses why it is such an attractive drug target and what this could entail.
Asthma is considered to be one of the world's most common diseases affecting the population, and is also a life-threatening condition affecting patients'.